Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Finished Goods (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Finished Goods for 9 consecutive years, with $25.0 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 8.7% to $25.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.0 million through Dec 2025, up 8.7% year-over-year, with the annual reading at $25.0 million for FY2025, 8.7% up from the prior year.
  • Finished Goods for Q4 2025 was $25.0 million at Ultragenyx Pharmaceutical, up from $23.0 million in the prior quarter.
  • The five-year high for Finished Goods was $26.7 million in Q2 2025, with the low at $4.9 million in Q2 2022.
  • Average Finished Goods over 5 years is $13.5 million, with a median of $12.1 million recorded in 2023.
  • The sharpest move saw Finished Goods decreased 13.08% in 2022, then soared 107.99% in 2023.
  • Over 5 years, Finished Goods stood at $5.7 million in 2021, then surged by 62.04% to $9.3 million in 2022, then skyrocketed by 62.82% to $15.1 million in 2023, then skyrocketed by 52.22% to $23.0 million in 2024, then increased by 8.7% to $25.0 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $25.0 million, $23.0 million, and $26.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.